1YBelow half the group
Rank 43 of 63 funds
Return +18.22%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 43No. 1 is SCBGENOME(E) +68.99%
United Global Healthcare Fund
Shows where this fund stands in its group. Not investment advice · Data as of 4 Nov 2026
UGH invests through the master fund United Global Healthcare Fund 99.76%
This fundUGH
The fund that actually investsUnited Global Healthcare FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY9.20%
Merck & MRK5.45%Data as of 31 Oct 2026 · Top 6 shown, the rest grouped as Other · per UOB fact sheet
Over the past year it trailed half its group; over 5 years it returned −1.85% per year (Below half the group)
No. 1 is SCBGENOME(E) +68.99%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 4 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | 7Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +9.81% | +4.38% | +5.26% | +11.29% | +10.42% | +16.32% | +18.22% | +18.91% | −8.90% | +25.07% | +53.91% |
Largest drawdown in the selected period −33.45% Previous peak 2 Sep 2021 (NAV 18.3541) → Trough 14 May 2025 (NAV 12.2142) · Not back to the previous peak as of 4 Nov 2026
Currently −10.33% from the peak NAV of 18.3541 (2 Sep 2021)
Over 5 years, UGH returned -0.12 per unit of volatility, ranking 23 of 33 funds · The highest is FP HCARE-A (0.44)
(1) กองทุนจะลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศ ชื่อ United Global Healthcare Fund โดยเป็น Authorised scheme ที่จดทะเบียนในประเทศสิงคโปร์ (Singapore) และอยู่ภายใต้กฎหมายที่เกี่ยวข้องของประเทศสิงคโปร์ โดยอยู่ภายใต้การกำกับดูแลของ Monetary Authority of Singapore (MAS) ซึ่งเป็นสมาชิกของ… Its largest holdings are หน่วยลงทุน : United Global Healthcare Fund - Class SGD Acc (Ref.USD) 99.76% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 5 Sep 2014, its NAV has fallen as much as −33.45% from its peak.
Actual total expense ratio (TER) 1.88% a year, against a ceiling of 5.35%. Management fee 1.61%. Front-end fee 1.50%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 0.01 THB, subsequent purchases 0.01 THB. Buy orders accepted until 15:30, sell orders until 14:00, and redemption proceeds are paid T+5
Hedged at the manager's discretion. As of 30 Sep 2026, 96.38% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · UGH: no dividends, TER 1.88% · UGH-SSF: no dividends, TER 1.88%
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Unitedhealth Group UNH4.36%
AstraZeneca AZN.L4.34%
Intuitive Surgical ISRG2.89%
GSK2.80%
ABBVIE ABBV2.77%
Vertex Pharmaceuticals VRTX2.58%
Edwards Lifesciences EW2.37%Eli Lilly and Co LLYDiabetes and weight-loss drugs
Merck & MRKHospitals, medicines and medical equipment
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
Hospitals, medicines and medical equipment
AstraZeneca AZN.LHospitals, medicines and medical equipment
Intuitive Surgical ISRGHospitals, medicines and medical equipment
GSK GSKHospitals, medicines and medical equipment
ABBVIE ABBVHospitals, medicines and medical equipment
Makes cystic fibrosis drugs and a gene-editing therapy for thalassaemia
US company that makes replacement heart valves fitted through a catheter, without open heart surgery
Based on the master fund's share of this fund's value (99.76% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 31 Oct 2026 · fact sheet from UOB · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +22.37% per year
No. 1 is FP HCARE-A +6.71% per year
| +64.57% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −0.9 | +2.6 | −6.8 | −0.4 | +1.1 | +5.9 | −1.6 | +4.3 | −3.2 | +7.4 | +1.8 | · | +9.8* |
| 2025 | +4.9 | −1.6 | −3.0 | −2.1 | −5.0 | +0.9 | −2.5 | +4.0 | +2.7 | +4.9 | +8.7 | −1.2 | +10.1 |
| 2024 | +0.6 | +2.1 | +1.2 | −3.3 | +2.4 | +2.5 | +2.0 | +3.7 | −4.9 | −4.6 | −2.2 | −7.3 | −8.1 |
| 2023 | −0.4 | −4.6 | +0.7 | +3.7 | −1.8 | +3.5 | −0.4 | −2.0 | −4.3 | −5.1 | +5.0 | +4.3 | −2.1 |
| 2022 | −11.5 | +1.2 | +2.8 | −7.2 | −1.0 | −0.2 | +5.0 | −5.6 | −4.1 | +6.9 | +2.7 | −2.0 | −13.6 |
